Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

HP 802247

Next Previous
Drug Profile

HP 802247

Alternative Names: Allogeneic human skin replacement - Smith & Nephew Biotherapeutics; Allox™; DFB Healthpoint allogeneic human skin replacement; HP-802247; Human skin replacement - Smith & Nephew Biotherapeutics

Latest Information Update: 02 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Healthpoint
  • Developer Smith & Nephew Biotherapeutics
  • Class Cell therapies; Skin disorder therapies
  • Mechanism of Action Fibrinogen replacements; Tissue replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Leg ulcer; Wounds

Most Recent Events

  • 23 Feb 2015 Smith & Nephew terminate a phase III trial in Leg ulcer in Czech Republic, Poland, Hungary, Belgium and Germany due to the outcome of previous study (NCT01853384)
  • 16 Jan 2015 Smith & Nephew terminates phase II trial in Leg ulcer in USA (NCT02154087)
  • 01 Dec 2014 Healthpoint completes a phase III trial for Leg ulcer in USA and Canada (NCT01656889)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top